The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19): study protocol for an investigator-driven randomized controlled clinical trial in primary health care—COLCHICOVID study
Abstract Background There is no strong evidence that any drug is beneficial either for the treatment of SARS-CoV-2 disease or for post-exposure prophylaxis. Therefore, clinical research is crucial to generate results and evaluate strategies against COVID-19. Primary care (PC) centers, the first leve...
Main Authors: | Elena Bustamante Estebanez, Lucía Lavín Alconero, Beatriz Josa Fernández, Monica Gozalo Marguello, Juan Carlos López Caro, Jonathan Diez Vallejo, Marta Fernandez Sampedro, Pedro Muñoz Cacho, Carlos Richard Espiga, María Mar García Saiz |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-021-05544-7 |
Similar Items
-
What is the lowest lethal dose of colchicine?
by: Vanyo Mitev
Published: (2023-11-01) -
Colchicine Overdose in a Suicidal Attempt
by: Fatemeh Eghbali, et al.
Published: (2019-10-01) -
Effects of colchicine on cardiac functions
by: Yusuf Ziya Şener, et al.
Published: (2019-11-01) -
Clinical, Laboratory, and Electrocardiographic Findings in Colchicine Toxicity: 10 Years of Experience
by: Mehdi Sheibani, et al.
Published: (2022-05-01) -
Colchicine for gout
by: M. S. Eliseev, et al.
Published: (2021-08-01)